Patents by Inventor Burkhard Haase

Burkhard Haase has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfonylaminocarboxylic acids
    Patent number: 7160903
    Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: January 9, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase
  • Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
    Publication number: 20050255071
    Abstract: A preparation comprising a compound which essentially prevents the enterohepatic circulation of nucleotide synthesis inhibitors or antagonizes the action of the nucleotide synthesis inhibitors with a displacement in time, and a nucleotide synthesis inhibitor such as brequinar, mycophenolatemofetil (2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoate), methotrexate, mizoribine and compounds of formulae (I) and (II) is suitable for the treatment of immunological disorders, cancer, or in transplantations.
    Type: Application
    Filed: July 11, 2005
    Publication date: November 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Jurgen Lindner, Burkhard Haase
  • Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Patent number: 6815440
    Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: November 9, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Method for finding nucleotide synthesis inhibitors having fewer side effects
    Patent number: 6716411
    Abstract: The invention relates to a method for finding nucleotide synthesis inhibitors which have a better therapeutic window. An efficacious dose of a nucleotide synthesis inhibitor is administered to a mammal. The concentration of the nucleotide synthesis inhibitor in the blood of the mammal is observed and it is determined whether the nucleotide synthesis inhibitor has a half-life which is shorter than that of N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide. The invention also relates to a method of using nucleotide synthesis inhibitors in the treatment of immunological diseases.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: April 6, 2004
    Assignee: Aventis Pharma Deustschland GmbH
    Inventors: Jürgen Lindner, Burkhard Haase
  • Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids
    Publication number: 20030176432
    Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Type: Application
    Filed: March 3, 2003
    Publication date: September 18, 2003
    Applicant: Aventis Pharma Deutschland GmbH.
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Patent number: 6573277
    Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: June 3, 2003
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Sulfonylaminocarboxylic acids
    Publication number: 20030087945
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 13, 2002
    Publication date: May 8, 2003
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase
  • Sulfonylaminocarboxylic acids
    Patent number: 6451824
    Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: September 17, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase
  • Substituted diaminocarboxylic acids
    Patent number: 6355673
    Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: March 12, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Bernhard Neises, Günter Billen
  • Method for finding nucleotide synthesis inhibitors having fewer side effects
    Publication number: 20020006381
    Abstract: The invention relates to a method for finding nucleotide synthesis inhibitors which have a better therapeutic window. An efficacious dose of a nucleotide synthesis inhibitor is administered to a mammal. The concentration of the nucleotide synthesis inhibitor in the blood of the mammal is observed and it is determined whether the nucleotide synthesis inhibitor has a half-life which is shorter than that of N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide. The invention also relates to a method of using nucleotide synthesis inhibitors in the treatment of immunological diseases.
    Type: Application
    Filed: December 13, 2000
    Publication date: January 17, 2002
    Inventors: Jurgen Lindner, Burkhard Haase
  • N-arylsulfonylamino acid omega-amides
    Patent number: 6335333
    Abstract: Compounds of the formula I: stereoisomeric forms, and physiologically tolerable salts thereof are suitable for the production of pharmaceuticals for the therapy and prophylaxis of disorders involving matrix-degrading metalloproteinases.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: January 1, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Wilfried Schwab, Werner Thorwart, Manfred Schudok, Burkhard Haase
  • Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids
    Publication number: 20010011134
    Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Type: Application
    Filed: February 12, 2001
    Publication date: August 2, 2001
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and carboxyclic acids
    Patent number: 6207672
    Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: March 27, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • N-arylsulfonylamino acid omega-amides
    Patent number: 6201130
    Abstract: Compounds of the formula I: stereoisomeric forms, and physiologically tolerable salts thereof are suitable for the production of pharmaceuticals for the therapy and prophylaxis of disorders involving matrix-degrading metalloproteinases.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: March 13, 2001
    Assignee: Aventis Pharma Duetschland GmbH
    Inventors: Wilfried Schwab, Werner Thorwart, Manfred Schudok, Burkhard Haase
  • Substituted diaminocarboxylic acids
    Patent number: 6159995
    Abstract: Compounds of formula (I) ##STR1## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: December 12, 2000
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Bernhard Neises, Gunter Billen